Delta Lloyd’s Puma Biotechnology PBYI Stock Holding History

Delta Lloyd’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,992	Closed	-$233K	–	689
2015 Q2	$233K	Buy	+1,992	New	+$361K	0.01%	661

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Delta Lloyd's PBYI Position: Q3 2015 in Review

Delta Lloyd sold out of Puma Biotechnology (PBYI) in Q3 2015, closing a stake of 1,992 shares — an estimated $233K sold.

Delta Lloyd first reported a position in PBYI in Q2 2015 and held it in 1 quarter. The position peaked at $233K in Q2 2015. 163 funds tracked by Wall St. Rank hold PBYI as of Q3 2015.

Delta Lloyd reported no remaining Puma Biotechnology position as of Q3 2015 after selling out during the quarter.
Delta Lloyd sold 1,992 Puma Biotechnology shares in Q3 2015, an estimated $233K.
Delta Lloyd first reported a position in Puma Biotechnology in Q2 2015 and held it in 1 quarter.
Delta Lloyd's Puma Biotechnology position peaked at $233K in Q2 2015.
163 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2015.

Based on Delta Lloyd's 13F filing for Q3 2015, filed 5 Nov 2015.